Cognitive Function As an Emerging Treatment Target for Marijuana Addiction

Overview

Journal Exp Clin Psychopharmacol

Publisher American Psychological Association

Specialty Pharmacology

Date 2010 Apr 14

PMID 20384422

Citations 27

Authors

Mehmet Sofuoglu

Dawn E Sugarman

Kathleen M Carroll

Affiliations

Soon will be listed here.

Abstract

Cannabis is the most widely used illicit substance in the world, and demand for effective treatment is increasing. However, abstinence rates following behavioral therapies have been modest, and there are no effective pharmacotherapies for the treatment of cannabis addiction. We propose a novel research agenda and a potential treatment strategy, based on observations that both acute and chronic exposure to cannabis are associated with dose-related cognitive impairments, most consistently in attention, working memory, verbal learning, and memory functions. These impairments are not completely reversible upon cessation of marijuana use, and moreover may interfere with the treatment of marijuana addiction. Therefore, targeting cognitive impairment associated with chronic marijuana use may be a promising novel strategy for the treatment of marijuana addiction. Preclinical studies suggest that medications enhancing the cholinergic transmission may attenuate cannabis-induced cognitive impairments, but these cognitive enhancing medications have not been examined in controlled human studies. Preliminary evidence from individuals addicted to other drugs suggests that computerized cognitive rehabilitation may also have utility to improve cognitive function in marijuana users. Future clinical studies optimally designed to measure cognitive function as well as drug use behavior would be needed to test the efficacy of these treatments for marijuana addiction.

Citing Articles

Trends in Cannabis-positive Urine Toxicology Test Results: US Veterans Health Administration Emergency Department Patients, 2008 to 2019.

Fink D, Malte C, Cerda M, Mannes Z, Livne O, Martins S J Addict Med. 2023; 17(6):646-653.

PMID: 37934524 PMC: 10766071. DOI: 10.1097/ADM.0000000000001197.

A pilot study investigating cognitive impairment associated with opioid overdose.

Mahoney 3rd J, Winstanley E, Castillo F, Luba R, Marton J, Alschuler D Drug Alcohol Depend. 2023; 247:109865.

PMID: 37094488 PMC: 10230403. DOI: 10.1016/j.drugalcdep.2023.109865.

Construct validity of DSM-5 cannabis use disorder diagnosis and severity levels in adults with problematic substance use.

Fink D, Shmulewitz D, Mannes Z, Stohl M, Livne O, Wall M J Psychiatr Res. 2022; 155:387-394.

PMID: 36182768 PMC: 9590423. DOI: 10.1016/j.jpsychires.2022.09.016.

Varenicline as a treatment for cannabis use disorder: A placebo-controlled pilot trial.

McRae-Clark A, Gray K, Baker N, Sherman B, Squeglia L, Sahlem G Drug Alcohol Depend. 2021; 229(Pt B):109111.

PMID: 34655945 PMC: 8665036. DOI: 10.1016/j.drugalcdep.2021.109111.

Cognitive Remediation as an Adjunct Treatment for Substance Use Disorders: A Systematic Review.

Nardo T, Batchelor J, Berry J, Francis H, Jafar D, Borchard T Neuropsychol Rev. 2021; 32(1):161-191.

PMID: 33871785 DOI: 10.1007/s11065-021-09506-3.

References

Fals-Stewart W, Lam W . Computer-assisted cognitive rehabilitation for the treatment of patients with substance use disorders: a randomized clinical trial. Exp Clin Psychopharmacol. 2010; 18(1):87-98. DOI: 10.1037/a0018058. View

Nordstrom B, Levin F . Treatment of cannabis use disorders: a review of the literature. Am J Addict. 2007; 16(5):331-42. DOI: 10.1080/10550490701525665. View

Stephens R, Babor T, Kadden R, Miller M . The Marijuana Treatment Project: rationale, design and participant characteristics. Addiction. 2002; 97 Suppl 1:109-24. DOI: 10.1046/j.1360-0443.97.s01.6.x. View

Camicioli R, Gauthier S . Clinical trials in Parkinson's disease dementia and dementia with Lewy bodies. Can J Neurol Sci. 2007; 34 Suppl 1:S109-17. DOI: 10.1017/s0317167100005679. View

McDonald J, Schleifer L, Richards J, de Wit H . Effects of THC on behavioral measures of impulsivity in humans. Neuropsychopharmacology. 2003; 28(7):1356-65. DOI: 10.1038/sj.npp.1300176. View

Mishima K, Egashira N, Matsumoto Y, Iwasaki K, Fujiwara M . Involvement of reduced acetylcholine release in Delta9-tetrahydrocannabinol-induced impairment of spatial memory in the 8-arm radial maze. Life Sci. 2002; 72(4-5):397-407. DOI: 10.1016/s0024-3205(02)02274-9. View

Collins D, Pertwee R, Davies S . Prevention by the cannabinoid antagonist, SR141716A, of cannabinoid-mediated blockade of long-term potentiation in the rat hippocampal slice. Br J Pharmacol. 1995; 115(6):869-70. PMC: 1909030. DOI: 10.1111/j.1476-5381.1995.tb15889.x. View

Bohme G, Laville M, Ledent C, Parmentier M, Imperato A . Enhanced long-term potentiation in mice lacking cannabinoid CB1 receptors. Neuroscience. 2000; 95(1):5-7. DOI: 10.1016/s0306-4522(99)00483-2. View

Berlanga M, Olsen C, Chen V, Ikegami A, Herring B, Duvauchelle C . Cholinergic interneurons of the nucleus accumbens and dorsal striatum are activated by the self-administration of cocaine. Neuroscience. 2003; 120(4):1149-56. DOI: 10.1016/s0306-4522(03)00378-6. View

10.

Everitt B, Hutcheson D, Ersche K, Pelloux Y, Dalley J, Robbins T . The orbital prefrontal cortex and drug addiction in laboratory animals and humans. Ann N Y Acad Sci. 2007; 1121:576-97. DOI: 10.1196/annals.1401.022. View

11.

Louis W, Jarrott B, Conway E . Sites of actions of alpha 2 agonists in the brain and periphery. Am J Cardiol. 1988; 61(7):15D-17D. DOI: 10.1016/0002-9149(88)90458-4. View

12.

Solinas M, Scherma M, Tanda G, Wertheim C, Fratta W, Goldberg S . Nicotinic facilitation of delta9-tetrahydrocannabinol discrimination involves endogenous anandamide. J Pharmacol Exp Ther. 2007; 321(3):1127-34. DOI: 10.1124/jpet.106.116830. View

13.

Solowij N, Battisti R . The chronic effects of cannabis on memory in humans: a review. Curr Drug Abuse Rev. 2009; 1(1):81-98. DOI: 10.2174/1874473710801010081. View

14.

Sewell R, Poling J, Sofuoglu M . The effect of cannabis compared with alcohol on driving. Am J Addict. 2009; 18(3):185-93. PMC: 2722956. DOI: 10.1080/10550490902786934. View

15.

Chambers C, Garavan H, Bellgrove M . Insights into the neural basis of response inhibition from cognitive and clinical neuroscience. Neurosci Biobehav Rev. 2008; 33(5):631-46. DOI: 10.1016/j.neubiorev.2008.08.016. View

16.

Tarditi A, Caricasole A, Terstappen G . Therapeutic targets for Alzheimer's disease. Expert Opin Ther Targets. 2009; 13(5):551-67. DOI: 10.1517/14728220902865614. View

17.

Vocci F . Cognitive remediation in the treatment of stimulant abuse disorders: a research agenda. Exp Clin Psychopharmacol. 2008; 16(6):484-97. DOI: 10.1037/a0014101. View

18.

Fried P, Watkinson B, Gray R . Neurocognitive consequences of marihuana--a comparison with pre-drug performance. Neurotoxicol Teratol. 2005; 27(2):231-9. DOI: 10.1016/j.ntt.2004.11.003. View

19.

Farlow M . A clinical overview of cholinesterase inhibitors in Alzheimer's disease. Int Psychogeriatr. 2003; 14 Suppl 1:93-126. DOI: 10.1017/s1041610203008688. View

20.

Nava F, Carta G, Battasi A, Gessa G . D(2) dopamine receptors enable delta(9)-tetrahydrocannabinol induced memory impairment and reduction of hippocampal extracellular acetylcholine concentration. Br J Pharmacol. 2000; 130(6):1201-10. PMC: 1572179. DOI: 10.1038/sj.bjp.0703413. View